IN2014DN03247A - - Google Patents
Info
- Publication number
- IN2014DN03247A IN2014DN03247A IN3247DEN2014A IN2014DN03247A IN 2014DN03247 A IN2014DN03247 A IN 2014DN03247A IN 3247DEN2014 A IN3247DEN2014 A IN 3247DEN2014A IN 2014DN03247 A IN2014DN03247 A IN 2014DN03247A
- Authority
- IN
- India
- Prior art keywords
- progestin
- estrogen
- disclosed
- composition
- transdermal delivery
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161555546P | 2011-11-04 | 2011-11-04 | |
US201261645778P | 2012-05-11 | 2012-05-11 | |
PCT/US2012/063314 WO2013067346A1 (en) | 2011-11-04 | 2012-11-02 | Dermal delivery compositions and methods |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014DN03247A true IN2014DN03247A (ja) | 2015-05-22 |
Family
ID=47278507
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN3247DEN2014 IN2014DN03247A (ja) | 2011-11-04 | 2012-11-02 |
Country Status (16)
Country | Link |
---|---|
US (3) | US9364487B2 (ja) |
EP (1) | EP2773333B1 (ja) |
JP (1) | JP6316749B2 (ja) |
KR (1) | KR20140088199A (ja) |
CN (1) | CN103957899A (ja) |
AU (1) | AU2012332254B2 (ja) |
BR (1) | BR112014010670A2 (ja) |
CA (1) | CA2854164C (ja) |
EA (1) | EA026664B1 (ja) |
ES (1) | ES2762460T3 (ja) |
HK (2) | HK1200317A1 (ja) |
IL (1) | IL232258A0 (ja) |
IN (1) | IN2014DN03247A (ja) |
MX (1) | MX353713B (ja) |
WO (1) | WO2013067346A1 (ja) |
ZA (1) | ZA201402988B (ja) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HRP20211377T1 (hr) | 2011-11-23 | 2022-01-07 | Therapeuticsmd, Inc. | Prirodne kombinirane hormonske supstitucijske formulacije i terapije |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
GB2521632B (en) * | 2013-12-23 | 2020-12-16 | Linscott Goode Steven | Vermin control compositions |
CA2947767A1 (en) | 2014-05-22 | 2015-11-26 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
CA2951284A1 (en) | 2014-07-29 | 2016-02-04 | Therapeuticsmd, Inc. | Transdermal cream |
US9844558B1 (en) | 2015-04-30 | 2017-12-19 | Amag Pharmaceuticals, Inc. | Methods of reducing risk of preterm birth |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
WO2017059070A1 (en) | 2015-09-29 | 2017-04-06 | Amag Pharmaceuticals, Inc. | Crystalline and amorphous form of 17-a- hydroxyprogesterone caproate |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
JP2019513709A (ja) | 2016-04-01 | 2019-05-30 | セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. | ステロイドホルモン薬学的組成物 |
MX2020004491A (es) * | 2017-10-30 | 2020-08-13 | Kaken Pharma Co Ltd | Preparacion externa para tratar tinea unguium. |
JP7220473B2 (ja) * | 2017-10-30 | 2023-02-10 | 帝國製薬株式会社 | 経皮投与製剤 |
CA3113399C (en) | 2018-09-19 | 2023-09-26 | Isp Investments Llc | Peroxide stable polymer composition and process for its preparation and applications thereof |
CN113455506A (zh) * | 2021-06-29 | 2021-10-01 | 无锡宏霸医疗科技有限公司 | 一种适用于日化产品的水相除臭去味剂及其制备方法 |
CN114259498B (zh) * | 2021-12-02 | 2023-04-28 | 南通联亚药业股份有限公司 | 一种包含去氧孕烯和炔雌醇的药物组合物及其制备方法和应用 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5656286A (en) * | 1988-03-04 | 1997-08-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
US5554381A (en) * | 1993-08-09 | 1996-09-10 | Cygnus, Inc. | Low flux matrix system for delivering potent drugs transdermally |
FR2739031B1 (fr) * | 1995-09-27 | 1997-11-21 | Lhd Lab Hygiene Dietetique | Systeme matriciel transdermique d'administration d'un oestrogene et/ou d'un progestatif a base de copolymere styrene-isoprene-styrene, procede de preparation et utilisation en therapeutique |
DE19700913C2 (de) * | 1997-01-14 | 2001-01-04 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System zur Abgabe von Hormonen |
IT1294748B1 (it) * | 1997-09-17 | 1999-04-12 | Permatec Tech Ag | Formulazione per un dispositivo transdermico |
GB9720470D0 (en) * | 1997-09-25 | 1997-11-26 | Ethical Pharmaceuticals South | Inhibition of crystallization in transdermal devices |
EP1197212A4 (en) * | 1999-07-01 | 2004-06-02 | Hisamitsu Pharmaceutical Co | ADHESIVE COMPOSITION FOR PERCUTANE ABSORPTION |
US7045145B1 (en) | 1999-11-24 | 2006-05-16 | Agile Therapeutics, Inc. | Transdermal contraceptive delivery system and process |
US7384650B2 (en) * | 1999-11-24 | 2008-06-10 | Agile Therapeutics, Inc. | Skin permeation enhancement composition for transdermal hormone delivery system |
PT1242012E (pt) * | 1999-11-24 | 2010-03-31 | Agile Therapeutics Inc | Sistema e processo melhorado de libertação transdérmica de contraceptivo |
DE50115609D1 (de) * | 2000-02-17 | 2010-10-14 | Basf Se | Wässrige Dispersion wasserunlöslicher organischer UV-Filtersubstanzen |
JP4422430B2 (ja) * | 2003-05-14 | 2010-02-24 | 帝國製薬株式会社 | エストロゲン及び/又はプロゲストゲン含有外用貼付剤 |
US20060121102A1 (en) * | 2004-09-27 | 2006-06-08 | Chia-Ming Chiang | Transdermal systems for the delivery of estrogens and progestins |
DK2985026T3 (da) * | 2005-04-15 | 2022-10-31 | Clarus Therapeutics Inc | Farmaceutiske leveringssystemer til hydrofobe lægemidler og sammensætninger dermed |
EP1893182B8 (en) * | 2005-05-26 | 2012-04-04 | Teva Women's Health, Inc. | Oral dosage forms comprising progesterone and method of making and using the same |
US10137135B2 (en) * | 2005-08-15 | 2018-11-27 | Allergan Sales, Llc | Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith |
DE102006050558B4 (de) * | 2006-10-26 | 2009-03-26 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System enthaltend Norelgestromin zur Kontrazeption und Hormonsubstitution |
RU2009117201A (ru) * | 2006-11-29 | 2011-01-10 | Вайет (Us) | Двухслойные таблетки на основе эстрогена/селективного модулятора эстрогенового рецептора и эстрогена/прогестина |
US20100178323A1 (en) | 2007-07-10 | 2010-07-15 | Agis Kydonieus | Dermal Delivery Device |
EP2167002B1 (en) | 2007-07-10 | 2016-04-20 | Agile Therapeutics, Inc. | Dermal delivery device with in situ seal |
EP2167001A4 (en) | 2007-07-10 | 2012-10-31 | Agile Therapeutics Inc | THERMAL DELIVERY DEVICE WITH ULTRASONIC WELDING |
WO2009142699A1 (en) * | 2008-05-19 | 2009-11-26 | The Procter & Gamble Company | Treatment of heart failure in women |
CA2756222A1 (en) * | 2009-03-27 | 2010-09-30 | Agile Therapeutics, Inc. | Transdermal delivery |
-
2012
- 2012-11-02 MX MX2014005294A patent/MX353713B/es active IP Right Grant
- 2012-11-02 EP EP12794803.2A patent/EP2773333B1/en active Active
- 2012-11-02 KR KR1020147014699A patent/KR20140088199A/ko not_active Application Discontinuation
- 2012-11-02 CA CA2854164A patent/CA2854164C/en active Active
- 2012-11-02 CN CN201280054080.8A patent/CN103957899A/zh active Pending
- 2012-11-02 AU AU2012332254A patent/AU2012332254B2/en not_active Ceased
- 2012-11-02 IN IN3247DEN2014 patent/IN2014DN03247A/en unknown
- 2012-11-02 ES ES12794803T patent/ES2762460T3/es active Active
- 2012-11-02 EA EA201400543A patent/EA026664B1/ru not_active IP Right Cessation
- 2012-11-02 WO PCT/US2012/063314 patent/WO2013067346A1/en active Application Filing
- 2012-11-02 US US13/667,632 patent/US9364487B2/en active Active
- 2012-11-02 JP JP2014540132A patent/JP6316749B2/ja active Active
- 2012-11-02 BR BR112014010670A patent/BR112014010670A2/pt not_active IP Right Cessation
-
2014
- 2014-04-24 ZA ZA2014/02988A patent/ZA201402988B/en unknown
- 2014-04-27 IL IL232258A patent/IL232258A0/en unknown
-
2015
- 2015-01-22 HK HK15100698.8A patent/HK1200317A1/xx unknown
- 2015-01-26 HK HK15100858.4A patent/HK1201152A1/xx unknown
-
2016
- 2016-05-11 US US15/151,966 patent/US20160250226A1/en not_active Abandoned
-
2018
- 2018-07-25 US US16/045,338 patent/US20180325916A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
IL232258A0 (en) | 2014-06-30 |
EP2773333A1 (en) | 2014-09-10 |
US9364487B2 (en) | 2016-06-14 |
HK1201152A1 (en) | 2015-08-28 |
NZ624117A (en) | 2016-02-26 |
JP6316749B2 (ja) | 2018-04-25 |
MX2014005294A (es) | 2014-09-22 |
HK1200317A1 (en) | 2015-08-07 |
KR20140088199A (ko) | 2014-07-09 |
WO2013067346A1 (en) | 2013-05-10 |
US20160250226A1 (en) | 2016-09-01 |
CN103957899A (zh) | 2014-07-30 |
EA026664B1 (ru) | 2017-05-31 |
ZA201402988B (en) | 2015-11-25 |
US20180325916A1 (en) | 2018-11-15 |
ES2762460T3 (es) | 2020-05-25 |
CA2854164A1 (en) | 2013-05-10 |
AU2012332254B2 (en) | 2017-06-22 |
BR112014010670A2 (pt) | 2017-05-09 |
US20130116222A1 (en) | 2013-05-09 |
EP2773333B1 (en) | 2019-10-02 |
MX353713B (es) | 2018-01-24 |
CA2854164C (en) | 2021-04-13 |
EA201400543A1 (ru) | 2014-09-30 |
AU2012332254A1 (en) | 2014-05-15 |
JP2014532719A (ja) | 2014-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014DN03247A (ja) | ||
MX2020013533A (es) | Formulaciones y terapias de reemplazo de combinacion de hormonas naturales. | |
MX365818B (es) | Formulaciones y terapias de reemplazo hormonal de combinacion naturales. | |
WO2010081032A3 (en) | Steroidal compositions | |
PH12015501738A1 (en) | Androgen receptor modulators and uses thereof | |
MX2013002975A (es) | Moduladores de receptores de estrogenos y usos de los mismos. | |
PH12014501351B1 (en) | Fluorinated estrogen receptor modulators and uses thereof | |
BR112014031824A2 (pt) | terapias de reposição hormonal transdérmica | |
PH12014502095A1 (en) | Estrogen receptor modulators and uses thereof | |
GB201200062D0 (en) | Estradiol oromucosal liquid compositions | |
NZ630805A (en) | Pharmaceutical combinations comprising a thionucleotide analog | |
MX2015011132A (es) | Moduladores policiclicos del receptor de estrogenos y sus usos. | |
MX2012007933A (es) | Composiciones de dexmedetomidina transdermicas topicas y metodos para su uso. | |
BR112013006331A2 (pt) | composições de fulvestranto e métodos de uso | |
MX2012000396A (es) | Metodos y composiciones para uso en tartamientos celulares. | |
MX2013004693A (es) | Composiciones de aripiprazol y metodos para su suministro transdermico. | |
NZ606730A (en) | Methods for treating antipsychotic-induced weight gain | |
NZ714288A (en) | Extended-release formulation for reducing the frequency of urination and method of use thereof | |
TN2014000059A1 (en) | Use of an aromatase inhibitor for the treatment of hypogonadism and related diseases | |
MX2016004392A (es) | Sistema de doble agente de ruptura para reducir daño a la formacion durante la fracturacion. | |
MX2014008693A (es) | Administracion transdermica de hormonas. | |
TN2014000418A1 (en) | Methods for treating cancer using pi3k inhibitor and mek inhibitor | |
NZ738063A (en) | Stable povidone-iodine compositions | |
NZ620005A (en) | Pharmaceutical composition comprising ebastine and fluticasone | |
UA51801U (ru) | Способ профилактики плацентарной дисфункции у женщин с наружным генитальным эндометриозом |